Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, Donat MS, Herr HW, Sogani P, dePalma D, Bajorin D. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder.. J Clin Oncol. 2002; 20(15) :3193-8
Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of T1 bladder cancer.. Urology 2002; 60(5) :824-825
Dalbagni G, Donat SM, Eschwege P, Herr HW, Zelefsky MJ. Results of high-dose brachytherapy (HDR-BRT), anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra. J Urol 2001; 166 :1759-1761
Dalbagni G, Ren Z-P, Herr HW, Cordon-Cardo C, Reuter VE. Genetic alterations in TP53 in recurrent urothelial cancer: A longitudinal study. CI Cancer Res 2001; 7 :1797-2801
Dalbagni G, Genega E, Hashibe M, Zhang Z-F, Russo P, Herr HW, Reuter V. Cystectomy for Bladder Cancer: A Contemporary Series. J Urol 2001; 165 :1111-1116
Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WDW, Dalbagni G. Toxicology and Pharmacokinetics of Intravesical Gemcitabine: A Preclinical Study in Dogs. CI Cancer Res 1999; 5 :2629-2637
Dalbagni G, Reschtschaffen T, Herr HW. Is Transurethral Biopsy of the Bladder Necessary After 3 Months to Evaluate Response to BCG Therapy. J Urol 1999; 162 :708-709
Dalbagni G, Zhang Z-F, Lacombe L, Herr HW. Male Urethral Carcinoma: Analysis of Treatment Outcome. Urology 1999; 53 :1126-1132
Dalbagni G, Zhang Z-F, Lacombe L, Herr HW. Female Urethral Carcinoma: Analysis of treatment outcome and a plea for a standardized management strategy. Br J Urol 1998; 82 :835-841
Return to Guido Dalbagni, MD, FACS Main Page.
